Source 1primary paper2023Chemical Science
Toolkit/light-activated plasmids
light-activated plasmids
Also known as: LA plasmids, LA-plasmids
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Light-activated plasmids are engineered DNA constructs in which photocleavable biotinylated nucleobases are installed at defined positions in T7 or CMV promoters and occupied by streptavidin to suppress transcription until light exposure. They were reported to control gene expression in both cell-free systems and mammalian cells.
Usefulness & Problems
Why this is useful
These constructs provide a way to place transcription under optical control by caging promoter function until illumination. The source literature further suggests potential future use for remote control of cellular activity and reduction of off-target toxicity, but this application remains prospective.
Source:
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
Problem solved
The tool addresses the problem of achieving externally triggered, promoter-level control of transgene expression from plasmid DNA. Specifically, it enables repression of T7- or CMV-driven transcription before illumination through promoter-localized chemical modification and streptavidin blocking.
Source:
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
Problem links
Need precise spatiotemporal control with light input
DerivedLight-activated plasmids are engineered DNA constructs in which photocleavable biotinylated nucleobases are installed at defined positions in T7 or CMV promoters and bound by streptavidin to suppress transcription until light exposure. They were reported to control gene expression in both cell-free systems and mammalian cells.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
PhotocleavagePhotocleavagePhotocleavagesteric blocking of promoter access by streptavidinsteric blocking of promoter access by streptavidinTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Input: Light
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: spectral hardware requirementoperating role: actuatorswitch architecture: cleavage
Implementation requires plasmids bearing photocleavable biotinylated nucleobases at specific positions within T7 or CMV promoters and subsequent streptavidin binding to impose transcriptional blockade. The supplied evidence supports use in cell-free systems and mammalian cells, but does not provide further construct design parameters, illumination conditions, or delivery details.
The available evidence comes from a single 2023 study and provides limited quantitative performance details in the supplied record. No independent replication, wavelength information, dynamic range, reversibility, or broad validation across additional promoters, organisms, or in vivo settings is documented here.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug light-activated-plasmids
To generate our light-activated (LA) plasmids
Source:
application resultsupports
The light-activated plasmids were successfully used to control expression in cell-free systems with a T7 promoter and in mammalian cells with a CMV promoter.
These LA-plasmids were then successfully used to control expression in both cell-free systems (T7 promoter) and mammalian cells (CMV promoter).
Source:
future applicationsupports
The light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
These light-activated plasmids might be used to remotely control cellular activity and reduce off-target toxicity for future medical use.
Source:
mechanism of actionsupports
Light-activated plasmids were generated by introducing photocleavable biotinylated nucleobases at specific sites across T7 and CMV promoters and binding streptavidin to sterically block access.
To generate our light-activated (LA) plasmids, photocleavable biotinylated nucleobases were introduced at specific sites across the T7 and CMV promoters on plasmids and bound to streptavidin to sterically block access.
Source:
Comparisons
Source-backed strengths
The reported system functioned in two distinct contexts: cell-free expression with a T7 promoter and mammalian cells with a CMV promoter. Its design is based on site-specific incorporation of photocleavable biotinylated nucleobases at promoter sites, providing a defined molecular mechanism for light-dependent activation.
Compared with alkynyl-functionalized photocleavable linker
light-activated plasmids and alkynyl-functionalized photocleavable linker address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: photocleavage; same primary input modality: light
Compared with Opto-Casp8-V2
light-activated plasmids and Opto-Casp8-V2 address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: photocleavage; same primary input modality: light
light-activated plasmids and randomly attached cage compounds on silencing oligonucleotides address a similar problem space.
Shared frame: same top-level item type; shared mechanisms: photocleavage; same primary input modality: light
Ranked Citations
- 1.